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	ABSTRACT 
LIBRARY SYNTHESIS OF THIOL-LINKED HYBRID INOSITIOL GLYCANS 
by Scott Chan 
Inositol phosphate glycans (IPGs) are natural pseudo-oligosaccharides that are 
produced in some mammalian cells upon stimulation by insulin. IPGs are capable of 
inducing insulin-like effects in insulin sensitive cells, making them viable drug targets for 
treating type II diabetes. However, the synthesis of highly insulin-mimetic synthetic IPGs 
is inefficient, requiring more than fifty steps. The development of hybrid inositol glycans 
(HIGAs) has mitigated this problem. HIGAs consists of a commercially available non-
carbohydrate moiety that is coupled with a saccharide group that requires only fifteen 
steps to synthesize. HIGAs are thus much more efficient to synthesize on large 
scales. This thesis describes the attempted synthesis of a library of HIGAs. The goal was 
to link five non-carbohydrate moieties to an IPG-like disaccharide via thiol-linkage. 
Three of the five non-carbohydrate moieties were negatively charged while the other two 
were neutral to study the effect that the negative charge has on the insulin-like activity of 
the HIGAs. The insulin-like activity can be quantified using a glucose uptake assay in 
cultured murine adipocytes. Unfortunately, the syntheses of the HIGAs were not 
completed but a novel precursor compound has been synthesized.  
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CHAPTER 1 
INTRODUCTION 
1.1 Diabetes: Type I vs. Type II 
Diabetes is a metabolic disease that results in the improper maintenance of a blood 
glucose level. A normal blood glucose level range from 4-7 mmol/l. To maintain this 
healthy range, either the peptide hormone glucagon or insulin is released 1. When blood 
glucose level is low, alpha cells of the pancreas secrete glucagon promoting the 
conversion of glycogen into glucose. This results in the elevation of blood glucose levels. 
When blood glucose level is high, beta cells of the pancreas secrete insulin. This causes 
the uptake and storage of glucose into insulin-sensitive cells. This phenomenon 
effectively lowers blood glucose level. Diabetes is characterized by hyperglycemia (high 
blood glucose levels), which is the result of faulty insulin signaling. 
Diabetes is categorized into type I and type II. Type I diabetes, previously referred to 
as juvenile diabetes, is an autoimmune disease in which the body attacks and destroys the 
beta cells of the pancreas. The destruction of beta cells prevents the synthesis and 
secretion of insulin2. Type II diabetes, the focus of this thesis, is often referred to as 
adult-onset diabetes. Type II diabetes is characterized by insulin resistance with a gradual 
desensitization of cells to insulin preventing insulin signal transduction3. 
1.2  Treating Type II Diabetes 
Type II diabetes currently affects 29.1 million people in the United States4. Patients 
with type II diabetes may suffer severe complications such as cardiovascular diseases, 
diabetic neuropathy, diabetic retinopathy, and diabetic nephropathy4. Early stages of type 
	 2 
II diabetes can be mitigated by altering diet, exercise, and insulin injections5. However, 
these methods are not sustainable solutions and life-long drug treatments are generally 
necessary. 
There are currently six types of medications for type II diabetes which include: 
biguanides, sulfonylureas, meglitinides, thiazolidinediones, glycogen-like peptide-1 
(GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors5. Metformin, a 
type of biguanide is the oldest and most widely used drug in the treatment of type II 
diabetes. Metformin effectively reduces hyperglycemia but the exact mode of action is 
unknown5. Sulfonylureas and meligtinides bind to sulfonylurea receptor 1 (SUR1) of 
potassium channels in pancreatic beta cells, causing the potassium channels to close 
resulting in a gradient. This allows an influx of calcium into the cell inciting the release 
of insulin6. Sulfonylureas bind to SUR1 with a stronger binding affinity and slower 
dissociation rate, thus inducing a longer lasting effect than meglitinides7. As for the 
thiazolidinediones, they are able to mitigate hyperglycemia by binding to the peroxisome 
proliferator-activated receptor gamma (PPAR-ϒ), inducing lipogenesis and converting 
glucose into fatty acids8. Finally, the GLP-1 receptor agonists and the DPP-4 inhibitors 
often referred to as the new generation drugs, were approved by the FDA in 2006. Both 
of these classes of drugs promote GLP-1 activity. GLP-1 is an incretin that, upon binding 
to the GLP-1 receptor, induces the release of insulin while inhibiting the secretion of 
glucagon. GLP-1 can be degraded by DPP-4 but DPP-4 inhibitors are able to prevent the 
degradation of GLP-1, therefore promoting GLP-1 activity9. 
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Unfortunately, the six classes of type II diabetes treatments have been linked to 
serious side effects such as lactic acidosis, cardiovascular disease, hemolytic anemia, 
liver failure, pancreatitis, pancreatic cancer, hypoglycemia, etc5. The treatments can be 
used as monotherapies but are more commonly used together. Although a greater anti-
diabetic effect is observed when the drugs are used in tandem, the prevalence of adverse 
effects are increased as well. For example, when metformin was used in conjunction with 
a thazolidinedine, there was a 6-fold increase in the incidence of pancreatitis5. Scientists 
are still searching for type II diabetes treatments with minimal side effects. Inositol 
phosphate glycans (IPGs) have been found to be a viable drug target due to their ability to 
induce insulin-like effects. 
1.3 Inositol Phosphate Glycans (IPGS) 
IPGs are naturally occurring pseudo-oligosaccharides that are derived from 
glycosylphosphatidylinositols (GPIs). There are two categories of GPIs consisting of GPI 
anchors and free GPIs. GPI anchors contain proteins that are attached at the terminal end 
while free GPIs lack a tethered protein. Structures of GPI anchors are highly conserved. 
They often contain an ethanolamine-mannose-α(l-2)-mannose-α(l-6)-mannose-α(l-4)-
glucoseamine-α(l-6)-myo-inositol group10. GPIs are ubiquitous in higher eukaryotic cells 
and can also be found in some protozoan parasites, bacteria, and yeast. GPIs play critical 
roles in hormone, growth factor, and cytokine signal transduction11. In 1986, Saltiel et al. 
treated bovine liver with insulin and observed that an enzyme modulator, which was later 
termed IPG, was released12. It was hypothesized that upon stimulation by insulin, a 
glycophosphatidylinositol specific phospholipase C (GPI-PLC) is activated and 
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hydrolytically cleaves the phosphodiester bond of the GPI anchor. A protease may also 
come in to cleave the protein to generate the IPG13. 
There are two structurally different types of IPGs that have been identified: IPG type 
A and IPG type P. IPG type A contains a myo-inositol group and glucosamine group 
while IPG type P consists of a chiro-inositol group and galactosamine group. The IPG 
type A that was isolated by Saltiel et al. in 1986 was observed to have the ability to 
stimulate insulin sensitive cells even in the absence of insulin 12. In 2003, the first 
structurally characterized putative insulin mediator IPG type P, INS-2, was isolated from 
beef liver by Larner et al.15 When INS-2 was administered intravenously to diabetic rats, 
a reduction in plasma glucose was observed. Increased levels of glucose incorporated into 
glycogen was also observed14.These findings from Saltiel et al. and Larner et al. 
strengthened the hypothesis that IPGs are secondary messengers of the insulin-signaling 
pathway.  
1.4 Insulin Signaling Pathways 
Insulin is a hormone that controls major biological functions of the cell such as: the 
activation of pyruvate dehydrogenase phosphatase, protein synthesis, cell proliferation, 
cell differentiation, etc. The biological functions induced by insulin that affect diabetes 
are glucose transport, activation of glycogen synthase, lipogenesis, and glycolysis, which 
are ways insulin sensitive cells store and breakdown glucose. Insulin, upon binding to the 
α-subunit of the insulin tyrosine kinase receptor (IR), induces a conformational change in 
the β-subunit of the IR. The conformational change in the β-subunit leads to the cross 
phosphorylation of cytosolic regions of the IR, recruiting insulin receptor substrates 1 and 
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2 (IRS-1 and IRS-2). IRS-1 and IRS-2 are then phosphorylated by the cytosolic kinase 
domain of the IR leading to the phosphorylation of phosphatidylinositiol-3,4-5-
triphosphate(PIP3) by IRS-1 and IRS-2. This leads to a phosphorylation cascade of 
phosphoinositol dependent kinase 1 (PDK1) and protein kinase B (PKB) in that order. 
After the activation of PKB, the insulin-signaling pathway diverges, resulting in glucose 
transport, activation of glycogen synthase, lipogenesis, and glycolysis15. 
1.4.1 Glucose transport 
Glucose transporter type 4 (GLUT-4) is a transporter protein that is responsible for 
the uptake of glucose through the cell membrane. GLUT-4 is phosphorylated by PKB 
directly. Alternatively, GLUT-4 may also be activated by insulin receptor substrate 
complex Cbl-CAP. Cbl-CAP, in tandem with adaptor protein CrkII and guanine 
exchange nucleotide exchange factor C3G, activates Tc10. Tc10 then induces GLUT-4 to 
be transferred in vesicles to the cell surface where GLUT-4 will then transport glucose 
into the cell15. 
1.4.2 Glycogen synthesis 
Glycogen synthesis is induced through the activation of PIP3 and PKB. 
Phosphorylated PIP3 activates protein phosphatase 1 (PP1), leading to the activation of 
glycogen synthase (GS) via dephosphorylation. GS is also alternatively activated via the 
inactivation of glycogen synthase kinase-3 (GSK-3). The phosphorylation of GSK is 
catalyzed by PKB and in turn deactivates GSK, leading to GS activity. These metabolic 
steps promote the conversion of glucose into glycogen15. 
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1.4.3 Lipogenesis 
Lipogenesis is promoted by the phosphorylation of PKB. Activated PKB binds to 
ATP citrate lyase (ACL), activating the enzyme via phosphorylation. ACL converts 
citrate into acetyl-CoAwhich then acts a building block for lipogenesis in the cytosol. 
Lipogenesis can be promoted indirectly through the decrease in lipolysis. PKB activates a 
series of proteins upstream, leading to the phosphorylation of phosphodiesterase 3B 
(PDE3B), which reduces the levels of cyclic adenosine monophosphate. This results in a 
decrease in protein kinase A (PKA) activity as well preventing the activation of hormone 
sensitive lipase (HSL). Lipolysis would thus fail to occur. Induction of lipogenesis causes 
glucose to be converted into fatty acids and by preventing lipolysis; fatty acids are not 
degraded15. 
1.5 IPGs as Secondary Messengers of the Insulin Signaling Pathway 
 
Multiple groups have done extensive research in attempts to elucidate the IG (inositol 
glycan) signaling pathway, but the pathway has yet to be fully understood. In 2000, 
Müller et al. used immune complex kinase assays to observe the non-tyrosine kinases 
(NRTK) pp59Lyn and pp125Fak. These experiments revealed that these two NRTKs 
were heavily involved in IG signaling, which led Müller et al. to propose a plausible 
signaling pathway16. Initially, binding of insulin to the insulin receptor causes the release 
of glycophosphatidylinositol-specific phospholipase C (GPI-PLC). GPI-LPC then cleaves 
GPIs, releasing IPGs from the cell surface. Upon the release of IPGs, GPI anchored 
proteins on the outer membrane are displaced from the IG receptor and relocated to a low 
density detergent insoluble glycolipid (lcDIG) region. Similarly, pp59Lyn is also 
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displaced to lcDIG regions in the cytosolic regions of the cell when IPGs bind to the IG 
receptor. The translocation of the pp59Lyn causes it to phosphorylate pp125Fak. Insulin 
receptor substrates 1 and 2 (IRS1/2) are then recruited by pp125Fak and phosphorylated 
by pp59Lyn. At this point, the IPG pathway and insulin signaling pathways converge, 
inducing glycogen synthase, lipogenesis, glycolysis, and glucose uptake15. 
1.6 Synthetic IPGs 
Since natural IPGs are extremely difficult to purify, scientists began synthesizing 
IPGs. In 1992, d’Alarcao and coworkers synthesized the first IPG to elicit an insulin 
response17. The goal was to synthesize an IPG modeled after the GPI anchor motif of 
mannose-α(l-2)-mannose-α(l-6)-mannose-α(l-4)-glucosamine-α(l-6)-myo-inositol. This 
led to the synthesis of the disaccharide IPG 1 and various analogs (Figure 1). When the 
analogues were tested using the lipogenesis assay, they were completely inactive except 
for IPG 1.  IPG 1 was found to have a 30-40% maximal insulin response (MIR). It was 
concluded by d’Alarcao and coworkers that an unacylated glucosamine and a cyclic 
phosphate were essential for synthetic IPGs to yield insulin mimetic responses17. 
Currently, the synthetic IPG to elicit the greatest MIR of >90% was synthesized by Frick 
et al. in 199818. In the same paper, it was reported that 45 other synthetic IPGs had 
promising insulin mimetic properties. It was confirmed that a synthetic IPG requires a 
cyclic phosphate present on the inositol and an unacylated glucosamine group to elicit 
insulin mimetic responses. It was also observed that anionic charges on the distal 
mannose enhance insulin-mimetic effects. Having established that these characteristics 
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are essential motifs for synthetic IPGs, various synthetic strategies have been developed 
to achieve the desired glycosidic linkages, and glucosamine and inositol connectivity. 
 
Figure 1. IPG 1 and various analogues synthesized by d'Alarcao and coworkers in 1992. 
1.6.1 Synthetic strategies for glycosidic linkages 
It is crucial that the glycosidic linkages are formed in a stereoselective and 
regioselective manner. This can be accomplished through various linkage methods and a 
series of protection and deprotection strategies. Commonly used strategies for 
stereoselective glycosylation involve thioglycosides, glycosyl halides, and imidate 
intermediates. 
1.6.1.1 Thioglycoside Strategy for Glycosylation  
The thioglycoside method is commonly used for stereoselective glycosidic linkages. 
This strategy involves the replacement of the anomeric hydroxyl group with a protected 
thiol group. To activate the thiol group for glycosylation, a metal salt is often used. The 
mechanism proposed by Ito and Ogawa was that a sulfonium salt is formed when the 1-
methylthiomannoside reacts with phenylselenyl triflate. The complex then rearranges into 
the more reactive selenonium salt (Scheme 1)19. The selenonium salt relies on the 1,2 
position-directing groups present on 1-thiomannoside to influence stereoselectivity. 
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Scheme 1. Proposed mechanism of 1-Thiomannoisde glycosylation catalyzed by 
selenium salt by Ito and Ogawa.  
 
A synthetic scheme was developed by Jaworek et al. in 2001 was designed to be 
modular. The mannoses can be quickly linked into varying sized oligosaccharides 
(Scheme 2)20.The two main building blocks were the 1-methylthiomannoside and p-
methoxyphenyl-2,3,4-tri-O-benzyl-α-D-mannopyranoside. Utilizing Ito and Ogawa’s 
phenylselenyl triflate method, α-glycosylation was achieved by the 1,2-trans directing 
groups present on the 1-methylthiomannoside.  This allows the 6-position hydroxyl 
present on p-methoxyphenyl-2,3,4-tri-O-benzyl-α-D-mannopyranoside to attack and 
attach favorably at the α-position. Once the glycosylation has occurred, the p-
methoxyphenyl group is removed and the 1-methylthiomannoside is formed to allow the 
subsequent glycosylation. This method can be repeated many times until the desired 
oligosaccharide length is formed. 
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Scheme 2. Formation of dimannoside utilizing thioglycoside glycosyl donor method by 
Jaworek et al. 
 
Another example of thioglycoside-promoted glycosylation is the synthesis of a 
Trypanosomacruzi derivative by Yashunsky et al.(Scheme 3)21. This was a (3+3) strategy 
where a tri-mannoside was formed and coupled to a pseudotrisaccharide. To form the tri-
mannoside, debenzoylation of the 2- and 6-positions followed by selective phenoxylation 
of the 6-position converted the dimannoside into a glycosyl acceptor. Coupling the 
glycosyl acceptor with another 1-thiomannoisde was catalyzed with methyl 
triflouromethanesulfonate. The 1,2-trans directing group present on the 1-
ethylthiomannoside afforded predominantly α glycosylation forming the desired tri-
mannoside.  
 
Scheme 3. Formation of a trimannoside derivative utilizing the thioglycoside method of 
glycosylation by Yashunsky et al. 
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1.6.1.2 Glycosyl halide strategy for glycosylation  
An alternative method of stereoselective glycosylation is through the usage of 
glycosyl halides. In a synthesis performed by Chakraborty et al., α-selective 
glycosylation was desired to link the mannosides and glucosamine. However, a mixture 
of α and β anomers were desired at the final coupling step of the inositol to the 
glucosamine (Scheme 5)22. To achieve α-selective glycosylation of the mannosides it is 
essential to have a glycosyl fluoride donor that is a D-mannoside derivative. Synthesis of 
the mannosyl fluoride donor was achieved by first deprotecting the 1-position hydroxyl 
by removing the methyl orthoester group. The 1-position was then selectively fluorinated 
using the diethylaminosulfur triflouride/THF method. Extensive studies carried out by 
Posner et al. for this fluorination method revealed that the 2-position directing group is 
vital for stereoselectivity.  It was also noted that utilizing THF as a solvent optimizes the 
reactivity23. The 2-position was then deactylated and subsequently orthogonally protected 
with allyl bromide to allow selective manipulation after inositol coupling. Coupling of 
the mannosyl fluoride donor to the glycosyl acceptor was promoted with silver triflate 
and bis(cyclopentadienyl)zirconium dichloride. Suzuki proposed that a zirconium 
perchlorate salt forms to activate the C-F bond, generating a highly reactive oxonium 
species to allow the hydroxyl group of the glycosyl acceptor to readily couple (Scheme 4) 
24. After coupling, the 1-position of the glucosamine is deprotected and fluorinated to 
convert it into a glycosyl donor for the inositol group.  
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Scheme 4. Proposed mechanism of zirconium catalyzed glycosylation by Suzuki et al. 
 
Scheme 5. Glycosylation utilizing glycosyl fluoride precursor by Chakrabortyet al. 
Glycosal bromides and chlorides are also widely used for glycosoyl halide promoted 
glycosylation. In the synthesis of a GPI anchor by Wu et al., a trimannoside precursor 
was required25. Starting from the D-mannose 1,2-orthoester, the 3,4,5 positions were 
deacetyled. This was followed by benzylation  orthogonal to the 2-position. The 1-
position was then deprotected to allow the chlorination at the anomeric position forming 
the glycosyl donor. The glycosyl chloride was then treated with silver triflate to activate 
the C-Cl bond in the presence of the 1-methylthiomannoside to allow α-glycosation. The 
dimannoside was subsequently deactylated for the next glycosylation step. To form the 
glycosyl bromide donor, the 1-methyl-α-D-mannoside was perbenzylated followed by 
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acetolysis of the 6-position. The 1-position was then brominated in the presence of HBr. 
Finally, the α-glycosylation with the Koenigs-Knorr method was catalyzed with silver 
triflate to form the trimannoside (Scheme 6). 
 
Scheme 6. Glycoslyation using glycosyl bromide and glycosyl chloride donors. 
1.6.1.3 Imidate intermediate strategy for glycosylation  
The method of glycosylation that will be utilized in this thesis is the 
trichloroacetimidate strategy. This method was developed by Schimdt et al. in 1994 with 
proposed mechanism and conditions for stereoselectivity (Scheme 7)26. It was reported 
that base-promoted activation of the anomeric hydroxyl-imidate intermediate traps 
stereochemistry for the mild acid catalyzed glycosylation in the presence of the glycosyl 
acceptor.  It was observed that from the 1-oxide ion, the β-imidate intermediate is 
favored. However, through retro-reaction and anomerization of the 1-oxide in a base 
catalyzed fashion, the α-position imidiate is produced. This led Schmidt et al. to optimize 
conditions with various bases such as K2CO3, NaH, and 1,8-diazabicyclo[5,4,0]undec-7- 
ene (DBU) to favor stereoselectivity.  
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Scheme 7. Proposed mechanism of imidate formation by Schmidt et al. 
An example of the imidate intermediate method is the synthetic scheme used by 
Muller et al. in 2002 for YCN-PIG 18,27. The first step in this approach was to attach the 
first mannose to the 4’ hydroxyl present on the glucosamine. Facilitated by the α-imidiate 
present on the D-mannoside, α-glycosylation was predominantly favored. To prime the 
compound for the next glycosylation step, the 1-position TBS group present on the 
glucosamine was removed with tetrabutylammonium fluoride. Next, the imidate 
intermediate was installed in the presence of K2CO3. The β-anomeric imidate promoted β 
glycosylation attaching the glucosamine to the inositol in the presence of trimethylsilyl 
tri-flouro-methansulfonate (TMSOTf). The glycosidic bonds of the last three mannoses 
were formed by the same strategy of deacylating the hydroxyls with sodium methoxide at 
the desired positions and stereoselectively attaching the subsequent mannoses via the 
trichloroacetimidate method (Scheme 8). 
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Scheme 8. Formation of a psuedotrisaccharide utilizing imidate-promoted glycosylation. 
An alternative method to installing the imidate intermediate is observed in the 
synthesis of a GPI anchor by Seeberger et al. that consisted of a hexasaccharide. The 
precursor 1,2-orthoester derivative of D-mannoside was initially deprotected to give an 
acetylated 2-position hydroxyl and a free anomeric hydroxyl28,29. Next, the imidate was 
selectively added at the α-anomeric position utilizing DBU as the base to form the 
glycosyal donor. The α imidate then drove α glycosylation in the presence of the mild 
acid TMSOTf coupling the two D-mannoside derivatives. The acetal located on the distal 
mannose was then removed to allow the next α-selective glycosylation with the same 
conditions to form the tri-mannoside building block (Scheme 9). 
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Scheme 9.Utilizing stereoselective imidate formation to promote α glycosylation. 
In the attempts to synthesize a Trypansoma cruzi-derived GPI, Nikolaev et al. used 
the strategy of forming the tri-mannoside first. The tri-mannoisde will then be coupled to 
a pseudodisaccharide containing the glucosamine and inositol group30. To form the 
glycosidic linkages, an alternative method of forming α imidates was used. The formation 
of the tetra-mannoside required a 1,2-orthoester D-mannoside derivative. The anomeric 
hydroxyl group was initially deprotected with trifluoroacetic acid to allow the formation 
of the imidate at the α position catalyzed by the base Cs2CO3. The α glycosylation was 
promoted by the α imidate in the presence of TMSOTf and the 2-position was 
subsequently deactylated with methanol and HCl to form a glycosyl acceptor. This 
method is repeated to promote α glycosylation forming the tri-mannoside building block 
(Scheme 10) 31,32. 
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Scheme 10. Cs2CO3 promoted installation of imidate to form glycosidic linkages of a tri-
mannoside. 
 
1.6.2 Formation of glucosamine 
The 2-deoxy-glucosamine derivatives are essential to IPGs and can be synthesized 
utilizing a variety of strategies. These methods may involve precursors with pre-existing 
2-position amine functionality or 2-position amine functionality can be introduced to the 
precursor compound. Through a series of selective protections and deprotections, the 
desired glucosamine donor can be achieved.  
In the synthesis of a Plasmodium falciparum GPI derivative by Guo et al. the 
glucosamine was achieved by first forming 1,6-anhydro-2-azido-2-deoxy-β-
glucopyranose.  This was carried out using the method proposed by Beau et al. in 1992 
(Scheme 11)33,34. From D-glucal, O-stannylation was afforded by reflux in presence of 
bis-tributylstannyl oxide. The compound was then subsequently treated with iodine. It 
was proposed that this compound isomerizes into an epoxide yielding a free hydroxyl at 
the 4-position which was protected with allyl bromide. Next, the epoxide allowed the 
trans-diaxial azido substitution of the 2-position with sodium azide in alkaline conditions 
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while also exposing the hydroxyl at the 3-position. The 3-position hydroxyl was 
subsequently orthogonally protected via benzylation, and ring-opening was achieved by 
acetolysis. To convert the glucosamine into a glycosyl donor, the 1-position O-acetyl was 
selectively deprotected and subsequently fluorinated achieving the desired glucosamine 
precursor (Scheme 12). 
 
Scheme 11. Proposed mechanism for epoxide formation by Beau et al. 
 
Scheme 12. Formation of glucosamine donor by Guo et al. 
Another method of forming the glucosamine was described by Berlin et al. in the 
synthesis of various glycosyl-inositol derivatives (Scheme 13)35. Starting with a 
peracetylated D-glucal precursor, the compound was deprotected with sodium methoxide 
and subsequently O-benzylated with benzyl bromide. Azidonitration was then carried out 
with ceric ammonium nitrate and sodium azide. This formed the 2-azido nitro-glucoside 
via double bond addition. The nitro group was then removed using sodium nitrite to 
afford the free hydroxyl at the anomeric position. The desired glucosamine donor was 
then achieved by treating the glucosamine with trichloroacetimidate in the presence of 
DBU.  
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Scheme 13. Glucosamine derivative afforded by azido nitration. 
Alternative modifications to achieve a desired glucosamine precursor can be observed 
in the synthesis of an IPG mediator by Martín-Lomas et al. in 200036.This method utilizes 
commercially available 2-dexoy-D-glucosamine hydrochloride (Scheme 14). The amine 
was converted into an azide by diazo transfer catalyzed by copper sulfate in the presence 
of triflic azide.  Wong et al. proposed that copper sulfate initially forms a complex with 
the amine present on the glucosamine to release a protonated ligand37. The nucleophilic 
amine group present on the copper complex then attacks the triflic azide group followed 
by deprotonation from the copper ligand. This results in the copper stabilized tetrazine. 
Breakdown of the complex results in the release of the desired azide and copper-trifyl 
imido complex (Scheme 15). After the diazo transfer, the masked glucosamine was 
subsequently peracetylated with acetic anhydride and protected thio functionality was 
installed at the anomeric position with thiophenol in the presence of BF3-etherate. The 
compound was then subsequently deacylated and the 4- and 6-positions were protected 
by the formation of the benzylidene acetal followed by O-benzylation of the 3-position. 
Selective ring opening utilizing sodium cyanoborohydride resulted in the 6-position O-
benzyl and the free hydroxyl at the 4-position. The 4-position hydroxyl was then 
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protected with TBS and hydrolysis of the thio group was carried out using 
bromosuccinimide in the presence of water. The glucosamine was then converted into a 
glycosyal donor by the installation of the imidate at the anomeric positon.  
 
Scheme 14. Protection of amine with diazotransfer method to yield glucosamine 
derivative. 
 
Scheme 15. Proposed mechanism of Copper catalyzed diazotransfer by Wong et al.  
 
1.6.3 Formation of inositol 
Optically pure inositol derivatives are highly sought after. It is important to 
orthogonally protect the hydroxyls to allow selective manipulation in the later stages of a 
synthetic scheme. Thus, the use of chiral building blocks is highly favorable to achieve 
the desired myo-inositols or chiro-inositols. Other strategies involve underivitized achiral 
inositol as a precursor as well.  
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Methods of obtaining inositol derivatives from underivitized myo- or chiro- inositol 
can be difficult to achieve due to the challenge of regioselective protection of the 
hydroxyl groups. A method developed by Vacca et al. to synthesize phosphorylated 
inositol glycosyl acceptors involved an underivatized myo-inositol precursor38.The myo-
inositol was protected with ethoxycylohexane resulting in three variously protected 
racemic mixtures (Scheme 16). After separation, the ketal derivative of myo-inositol was 
tosylated at the 3-position and subsequently treated with (1S)-(-)-camphanic acid to form 
the 6-camphanate esters. It was noted that at this point that separation of the two 
diastereomers was achievable. Upon triflate inversion of the undesired isomer utilizing 
the tetrabutylammonium nitrate method, the desired optically pure product is afforded. 
Deprotection of the triflate and the camphante, followed by the installation of the 
protected phosphate group resulted in the desired inositol glycosyl acceptor39 (Scheme 
17) . 
 
Scheme16. Racemic Products of inositol protected by ethoxycyclohexene. 
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Scheme 17. Utilizing D-camphanate to achieve resolution in the formation of inositol 
derivative. 
 
A similar method was used by Ogawa et al. in the synthesis of a Trypansoma brucei 
variant40,41. Starting from the dicyclohexylidene inositol derivative, the 6-position was 
selectively p-methoxybenzylated assisted by Bu2SnO and subsequently 1-O-allylated 
with vinyl bromide. Ring opening was achieved with acidic conditions followed by 
perbenzylation of the free hydroxyls to afford a racemic mixture. Similar to Vacca et al., 
deallylation of the 1-position followed by treatment of (1S)-(-)-camphanic acid afforded 
enantiomeric resolution and the desired diastereomer was isolated. To convert the inositol 
into a glycosyl donor, the p-methoxybenzyl group was removed from the 6-position and 
subsequently orthogonally protected via vinylation. The camphanate was removed by 
hydrolysis followed by 1-O-p-methoxbenzylation. Finally, the vinyl ether protecting 
group was removed to give a free 4-position hydroxyl for glycosylation (Scheme 18). 
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Scheme 18. Formation of an inositol glycosyl acceptor by Ogawa et al. 
 A widely use strategy is to utilize a D-xylose precursor to form the desired 
derivative inositol. Starting from the perbenzylated D-xylose, anomeric Wittig 
methylenation was carried out. Oxidation of the free hydroxyl group utilizing the Swern 
oxidation results in the formation of the aldehyde. The Grignard reaction yields the 
optically impure allyic alcohols. It was observed that, when the Grignard reaction was 
carried out in the presence of MgBr2-OEt2, the anti-diastereomer was favored 8:1. The 
alcohol was then protected with the TBS group and the epimers were separated followed 
by ozonolysis to afford the dialdehyde. The ring was then closed to favor the cis-diol 
using samarium diiodide19,42 (Scheme 19) .  
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Scheme 19. Formation of inositol derivative from D-xylose utilizing ozonolysis. 
An alternative method to the D-xylose strategy was proposed by d’Alarcao et al. to 
achieve the desired optically pure glycosyl acceptor. The methods were identical starting 
from the D-xylose precursor to the Grignard reaction forming the allyic alcohols (Scheme 
20). Ring closing was alternatively achieved through the Grubbs metathesis method to 
afford the optically pure conduritols43. The diastereomers of the conduritols can be 
separated at this step to afford the desired myo- or chiro-inositol with better yield and one 
fewer step than the ozonolysis method. The free hydroxyl can then be protected with TBS 
and the diol was installed using osmium tetroxide. The cyclic carbonate can be installed 
followed by the deprotection of TBS to afford the desired glycosyl acceptor.  
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Scheme 20. Formation of inositol derivative utilizing Grubb’s catalyst. 
1.6.4 Hybrid inositol glycans (HIGAs) 
In 2005, d’Alarcao et al. attempted to use IPGs as a novel drug delivery system in 
insulin mimetic cells44. A commercially available non-carbohydrate fluorescent moiety, 
the iodoacetamide derivative of Lucifer yellow, was attached to a thiol derivative of IPG 
1 forming the first hybrid inositol glycan (HIGA)(Figure 2). Lucifer yellow served both 
as a hypothetical drug and as a probe to determine whether or not IPGs could be 
successfully delivered into the cells. It was observed that the HIGA did not cross the cell 
membrane; therefore this particular HIGA was not a viable drug delivery system13. When 
the HIGA was subjected to the lipogenesis assay, a 47% MIR was recorded44. The 
increase in insulin activity between IPG 1 and the HIGA was accredited to the negative 
charges present on the Lucifer yellow derivative. Thus confirming the findings by Frick 
et al. The HIGA was synthesized in only 15 steps, which is significantly more efficient 
compared to the highly insulin mimetic IPGs synthesized by Frick et al.  
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Figure 2. The first hybrid inositol glycan synthesized. 
HIGAs are a growing area of interest because they are relatively simple to synthesize 
compared to synthetic IPGs, which led to the synthesis of compound 16 reported in 
Fulzele thesis45. It was presumed that the placement of the charges on the HIGA 
synthesized by d’Alarcao et al. was critical for to the insulin mimetic activity. The goal 
was to design an efficient synthesis for a compound containing a cyclic phosphate that 
can be easily coupled to a non-carbohydrate moiety containing an ionic charge. The 
precursor tri-O-benzyl-6-azido-deoxy-myo-inositol was formed initially. The azido group 
present on the precursor allows Huisgen 1, 3-dipolar-cycloaddition (“click” reaction) 
which is an efficient method for the addition of various functional groups.  Utilizing the 
“click” reaction, a protected thiol functionality was introduced to act as a link to the non-
carbohydrate moiety, and the cyclic phosphate group was added to the diol. After global 
deprotection, the thiol linkage was formed with the non-carbohydrate moiety 1,5-IADEN 
to form the desired HIGA. Various other non-carbohydrate moieties can be added to 
further investigate the correlation of insulin mimetic activity and positioning of ionic 
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charges on the non-carbohydrate moieties. HIGAs is a versatile group of synthetic IPGs 
that can be readily synthesized and manipulated to study potential insulin mimetic effects 
(Scheme 21). 
 
Scheme 21. Retrosynthetic scheme of HIGA compound 16 from Fulzele Thesis. 
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CHAPTER 2 
RESEARCH GOAL AND SYNTHETIC SCHEME 
2.1 Library Synthesis of Thio-linked HIGAs 
The goal was to synthesize a library of five novel HIGAs by attaching various 
commercially available thiol reactive non-carbohydrate moieties to a thiol derivative of 
the disaccharide synthesized by d’Alarcao et al. Three of the five non-carbohydrate 
moieties are negatively charged (Fluorescein-5-malemide, IAEDANS, and Alexa Flour 
350 C5-malemide), and the other two are net neutral (DACM and N-(1-
pyrene)malemide) (Figure 3). The purpose of using both charged and non-charged 
moieties was to determine whether the negative charges contribute to greater insulin 
activity.  
 
Figure 3. The five fluorescent non-carbohydrate moieties that are linked to the 
disaccharide to form the desired HIGAs. The three on the top are negatively charged at 
pH 7 while the two on the bottom are neutral at pH 7. 
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An efficient synthetic scheme to the disaccharide containing the glucosamine and 
myo-inositol has been well established by d’Alarcao et al. at Tufts University (Scheme 
22). The final steps to the synthesis of the disaccharide require the formation of a cyclic 
phosphate followed immediately by dissolving-metal reduction to globally remove the 
protecting groups. This step, however, exposes the disaccharide to harsh conditions. The 
cyclic phosphate group is susceptible to hydrolysis below pH 5 or above pH 8. The thiol 
group was chosen as the linker group for this reason. At pH 7, the cyclic phosphate group 
would be safe while the thiol group would be far more nucleophilic at pH 7 than the free 
hydroxyls and the amine group present in the disaccharide yielding a selective linkage at 
the 6-position (Figure 4). Another advantage of the thiol linkage is its ability to react 
readily with florescent moieties that are commercially available.  
 
Scheme 22. Retrosynthesis of IPG 1 depicting the global deprotection followed by the 
introduction of the cyclic phosphate. 
 
 
Figure 4. The thiol derivative of IPG 1 target used as a linker for non-carbohydrate 
attachment. 
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2.2 Formation of HIGA 
The HIGA consists of three main groups: the thiol derivative glucosamine group, the 
cyclic phosphate containing myo-inositol, and the non-carbohydrate moiety. The thiol 
derivative glucosamine was synthesized initially from a glucosamine precursor while the 
myo-inositol group was synthesized separately in our lab. The myo-inositol moiety 
originates in the glycosyl acceptor 18, which was attached via an alpha linkage to the 
glucosamine glycosyl donor 13 (Scheme 23). Finally, the non-carbohydrate moiety was 
attached forming the desired HIGA. 
 
Scheme 23. Retrosynthetic analysis of the thiol derivative of IPG-1 leading to the 
glucosamine glycosyl donor and then myo-inositol glycosyl acceptor. 
 
The synthesis of the glycosyl donor 13 was carried out by first protecting the amine 
group present on the glucosamine precursor 1 via diazotransfer to give 2 (Scheme 24).  
Compound 2 was then peracetylated in presence of acetic anhydride to afford 3. Selective 
deacetylation of the anomeric position was carried out using gaseous ammonia to yield 4. 
The free hydroxyl group was then protected using tertbutylsilyl chloride forming 5. 
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Global deacetylation with sodium methoxide resulted in the triol 6. The 4’and 6’hydroxyl 
groups were protected using benzylidene dimethyl acetal to yield 7, and the benzylidene 
ring was then selectively opened to the free 6’-hydroxyl compound 8. The 6’- hydroxyl 
group was made into a good leaving group via treatment with tosyl chloride, which led to 
10. The tosyl group was then replaced with lithium benzylthiolate to afford 11. The 
anomeric position was deprotected using tetrabutyl ammonium fluoride, giving 12. The 
glucosamine group was converted into a glycosyl donor by treatment with 
trichloroacetonitrile to produce trichloroacetimidate 13 (Scheme 23). 
Trimethylsilyl trifluoromethanesulfonate-promotedglycosylation of myo-inositol 18 
with the glucosamine donor 13 selectively yielded the α product 14. The cyclic carbonate 
group present on the myo-inositol group was subjected to hydrolysis with lithium 
hydroxide to yield the diol 15. The diol group was converted into a cyclic phosphate 
group in the presence of methylpyridinium phosphorodichloridate followed by a global 
deprotection using dissolving metal reduction method to yield disulfide 16, presumably 
because of air oxidation upon work-up. The disulfide was cleaved by treating 16 with 
tris(2-carboxyethyl)phosphine, and the fluorescent non-carbohydrate moieties are 
attached via thiol linkage in the presence of 25mM HEPES buffer (Scheme 24).  
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Scheme 24. Synthesis of Thiol-linked HIGAs. Reagents and conditions: (A) TfN3, H2O, 
CuSO4, Et3N  (B) Ac2O, pyr (C) NH3 , THF, MeOH (D) TBSCl, Im, CH2Cl2  (E) NaOMe, 
MeOH (F) BDMA, p-TsOH, CH3CN (G) 1. NaH, THF  0 °C to rt, 2. BnBr, TBAI, 0 °C 
to rt (H) BH3NHMe2, BF3 OEt2, CH2Cl2 (I) TsCl, Pyr (J) BnSLi, THF (K) TBAF, AcOH, 
THF  (L) Cl3CCN, K2CO3 (M) 18,TMSOTf, Et2O (N) LiOH, H2O, THF (O) 1. PCl2O2- 
MePy+, 2. Na, NH3, THF -78 °C, 3. NH4Cl (s), -78 °C, 4. CH3OH, -78 °C to rt (P) "X", 
25mM HEPES, TCEP pH 7.1, rt (X= non-carbohydrate moiety). 
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CHAPTER 3 
DISCUSSION 
3.1 Alternative Method to Protecting 6’ Hydroxyl 
 
Scheme 25: Dimethoxytritylation as alternative route to protecting the 6’ hydroxyl. 
 
Dimethoxyltritylation of the 6’ hydroxyl was pursued initially to form the protected 
6’ glucosamine. The tritylation method was thought to be a more favorable route 
compared to the benzylidene reaction due to the inefficient ring-opening step that occurs 
later on in the synthetic scheme. However, after attempting the reaction, the product 
obtained was unstable during analytical techniques. Degradation was observed on the 
TLC plates. This was most likely due to the acidic nature of silica, and during NMR 
analysis the product did not dissolve in CDCl3. Due to poor yield and stability of the 
tritylated product, the benzylidene route was pursued instead.  
3.2 Benzylidene Ring Opening 
 
Scheme 26: Possible regio-isomers that results from the benzylidene ring opening 
reaction. 
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There are many possible complications that may arise with the benzylidene ring 
opening reaction. The acidic nature of the BF3-etherate reagent may cause degradation 
due to the sensitivity of the silyl group present at the anomeric position (which was 
observed). The ring may also open to the unwanted 4’-OH product (Scheme 26). To 
further complicate the situation, the NMR spectrum of the 4’-OH isomer and the 6’-OH 
isomer are nearly identical. To verify that the desired compound was synthesized, the 
product was acylated. Theoretically, if the compound were the desired 6’-acylated 
isomer, the two geminal 6’ hydrogen peaks should shift further downfield and if it were 
the 4’-acylated product, only one peak would shift significantly further downfield. Upon 
acylation of the recovered compound, it was observed that two peaks had shifted 
downfield confirming that the desired product was synthesized.  
3.3 Alternative Route to Protecting 3’ Hydroxyl 
 
Scheme 27. Paramethoxybenzylation as an alternate route to protecting the 3’hydroxyl.  
The 3’ hydroxyl group can be alternatively paramethoxybenzylated. The 
paramethyozybenzylation reaction required the formation of a paramethoxybenzyl-
trichloroacetimidate reagent, which proved difficult to form. The reaction was extremely 
inconsistent, resulting in poor yields. It was observed during TLC monitoring of the 
reaction that the paramethoxybenzyl-trichloroacetimidate reagent was decreasing in 
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concentration while a spot at the baseline began to form. It was evident that the reagent 
was degrading before it could react with the starting material to form the desired product. 
The paramethoxybenzylation reaction also required the acidic reagent BF3-etherate, 
which may cleave the TBS group, resulting in further unwanted degradation products. 
This reaction was inefficient, resulting in poor yields and a high degree of degradation of 
the starting material and the reagent was observed. Therefore, this route was not pursued 
any further. 
3.4 Alternative 6’ Linkage  
 
Scheme 28. Using amine as an alternative 6’ linkage group. 
An alternative 6’ linkage was sought after due to the difficulty of preparing the BnSLi 
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values less than 5 and greater than 8, neutral conditions are ideal when adding the non-
carbohydrate moiety. The neutral conditions led to disulfide formation of the thiol 
compound at the 6’ position, and as previously reported by Turner, it was difficult to 
separate the dimer and purify the desired product. 
The strategy proposed to circumvent these problems was to attach phthalimide at the 
6’ position, which would then be readily hydrazinolyzed to generate an amine 
nucleophile (Scheme 28). The 6’tosyl group was expected to be readily displaced using 
potassium pthalimide. After coupling of the glucosamine with the inositol acceptor, 
lithium hydroxide and water can hydrolyze the cyclic carbonate function to yield a diol, 
and the phthalimide can be hydrazinolyzed to release a nucleophilic amine ready for non-
carbohydrate linkage. The diol can then be phosphorylated, and subsequently, the non-
carbohydrate moiety can be added. The major downside occurs at this step because the 
non-carbohydrate moiety is added prior to global deprotection. These conditions might be 
too harsh for the non-carbohydrate moiety. Also, compared to thiol linkage, the amine 
linkage requires three additional steps to form the HIGA from a common precursor, while 
the thiol linkage only requires one additional step.  
The method used was adopted from Coxon et al. with modifications to the reaction 
conditions46. Due to the relatively bulky nature of potassium phthalimide, this reaction did 
not go to completion at room temperature. To push this reaction forward, the amount of 
potassium phthalimide and heating were adjusted to find optimal conditions. The first 
attempt at this reaction was carried out with a 1:1 molar ratio of the glucosamine and 
potassium phthalimide while incrementally increasing the temperature by 10°C per hour 
	 37 
starting at 45°C. No reaction was observed in the first attempt. Degradation was noted that 
at 80°C as a baseline spot began to form on the TLC plate. Degradation was most likely 
due to the instability of the TBS group, and a combination of slight exposure of the 
reaction mixture to air and heat may have promoted hydrolysis. For the second attempt, a 
1:2 molar ratio of the glucosamine and potassium phthalimide was added to the reaction 
mixture. The temperature was increased by 5°C incrementally every hour starting at 45°C. 
After an hour at 65°C, it was observed the reaction began to move forward and 
degradation began to occur. After increasing the temperature to 75°C, degradation was 
occurring at a greater rate than desired product formation. The conditions for this 
experiment were optimized at 65°C for 3 hours with a 1:2 glucosamine to potassium 
phthalimide molar ratio.  The yield for this reaction was 46%.  
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CHAPTER 4 
GLUCOSE UPTAKE ASSAY 
The glucose uptake assay is a method used to measure the effectiveness of the HIGAs 
in vitro. The activity of glucose transporter isoform 4 (GLUT4) will reflect the level of 
insulin-like activity produced by the HIGAs. GLUT4 is unique compared to other 
glucose transporters. They are present in vesicles within insulin sensitive tissues such as 
skeletal tissues and adipose tissue while other glucose transporters are most commonly 
found on the plasma membrane47. The cell line chosen to carry out the glucose uptake 
assay was the 3T3-L1 mouse fibroblast cell line. Due to ability of the 3T3-L1 cell line to 
differentiate from their pre-adipocyte fibroblast phenotype to the adipocyte phenotype, 
this cell line is widely used to study glucose transport.  
4.1 3T3-L1 Differentiation 
For the experiment, frozen 3T3-L1 preadipocyte cells were purchased from ZenBio 
Inc. Upon thawing of the cells, the cells were distributed into cell culture dishes at 
approximately 5,000 cells/cm2 with the cells suspended in preadipocyte medium 
containing DMEM, HEPES, bovine calf serum, penicillin, streptomycin and 
amphotericin B. The cell cultures were maintained in an incubator at 37°C with 10% CO2 
until the cells reached confluency48. After an additional two days of incubation, 
differentiation of the fibroblasts into adipocyte cells was initiated by the introduction of 
differentiation medium containing DMEM, HEPES, fetal bovine serum, biotin, 
pantothenate, human insulin, dexamethasone, penicillin, streptomycin, amphotericin B, 3-
isobutyl-1-methylxanthine (IBMX), and PPAR-γ agonist. Dexamethasone and IBMX are 
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vital to the differentiation medium because they are both regulators of transcription 
factors associated with the CCAAT/enhancer binding proteins (C/EBPs). Dexamethasone 
is a synthetic glucocorticoid with enhanced binding affinity to the glucocorticoid receptor 
and promotes C/EBPγ gene expression upon binding. IBMX is a phospohdiesterase 
inhibitor that induces C/EBPβ gene expression, leading to differentiation of adipocyte 
cells49. Fully differentiated cells were maintained for another seven days in adipocyte 
medium containing DMEM, HEPES, fetal bovine serum, biotin, pantothenate, human 
insulin, dexamethasone, penicillin, streptomycin, and amphotericin B. 
4.2 Developing the Glucose Uptake Assay  
The glucose uptake assay methodology was adopted from Müller et al. with slight 
modifications49. Differentiated adipocyte cells were dislodged from the petri dish by 
treatment of trypsin and subsequently washed twice with PBS. Next, the dislodged cells 
were treated with 20µM cytochalasin B to disrupt any prior tubulin in order to measure 
specific glucose uptake activity promoted by insulin or the HIGA. As a control, another 
set of cells was not treated with cytochalasin B. Cells were subsequently incubated in 
200nM insulin for 30 minutes at37°C and, as a control, another set of cells was not 
treated with insulin. After the stimulation, the cells were incubated with 0.33µCi/ml of  2-
deoxy tritiated glucose for 20 minutes. It is important to use 2-deoxy tritiated glucose 
because once glucose has entered the cell, it may be broken down by various metabolic 
pathways 2-deoxy glucose will however, bypass these metabolic pathways. The cells 
were subsequently washed three times with ice cold PBS. Glucose uptake activity was 
measured by initially lysing the cells with 0.2M NaOH. A 30µL volume aliquot of cell 
	 40 
lysate was taken for Bradford assay to measure the amount of protein present while the 
rest of the cell lysate was added to 8 mL of scintillation cocktail. Results from the 
scintillator gave counts of tritiated 2-dexoy glucose per minute.  
To develop the glucose uptake assay, the idea was to conduct the experiment in three 
phases (Table 1). In the first phase, cells were either treated with insulin or without 
insulin. The purpose of this phase was to confirm if the presence of insulin would result 
in an increase in glucose uptake activity. As well as provide information on basal glucose 
uptake activity in the absence of insulin to act as the negative control.  
The next phase involved cells that were not treated with insulin, cells that were 
treated with insulin, cells that were treated with cytochalasin B, and cells treated with 
both cyotchalasin B and insulin. GLUT-4 transporters are present on the cell membrane 
and within vesicles in the cytoplasm at basal level. The treatment with cyotchalasin B 
would disrupt tubulin activity, preventing further translocation of GLUT-4 to the cell 
membrane. Cells treated solely with cytochalasin B would exhibit glucose uptake activity 
by pre-existing GLUT-4 on the cell membrane. Under the treatment of cytochalasin B in 
conjunction with insulin, cells would exhibit glucose uptake activity of GLUT-4 present 
on the cell membrane and activity induced by insulin. The cells treated with only insulin 
would exhibit glucose uptake activity by the GLUT-4 already present on the cell 
membrane, GLUT-4 in the cytoplasm, and glucose uptake activity induced by insulin. 
Therefore, taking the difference in activity from cells that were treated with only insulin 
by the activity from the cells that were treated with both insulin and cytochalasin B 
would yield information on specific glucose uptake activity induced by insulin.  
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In the final phase, the conditions were replicated from the second phase. The 
difference between the second phase and the final phase is the additional set of cells that 
are treated with HIGA in the presence or absence of cytochalasin B. This data will give 
the specific glucose uptake activity induced by the HIGA of interest and by comparing 
the specific glucose activity induced by the HIGA with specific glucose activity induced 
by insulin, this will determine the maximal insulin response exhibited by the HIGA. 
Table 1. Planned Phases to Develop Glucose Uptake Assay 
 
 
Note: Check marks represent what each plated with be treated 
 
4.3 Results of Glucose Uptake Assay  
Unfortunately, a reproducible glucose uptake assay was not established. One of the 
problems occurred during the Bradford Assay, which relies on a standard curve based on 
absorbance readings when coomassie blue dye reacts with known concentrations of 
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bovine serum albumin. The colorimeter that was used failed to give consistent 
absorbance readings of a single sample leading to an unreliable standard curve as well as 
unreliable readings for cell lysate samples. The major problem was contamination 
occurring frequently during the cell differentiation, and mature adipocyte cells were only 
achieved on two separate occasions.  With these problems, only phase one and phase two 
were attempted. 
Phase one of the glucose uptake assay was carried out with two sets of cells treated 
with insulin (WI1/WI2) and with two sets of cells that were not treated with insulin 
(WOI1/WOI2). Results obtained were as expected as cells that were treated with insulin 
on averaged had about 5 times greater count per min to microgram of protein than the 
cells that were not treated with insulin. There was some variation, however, since the 
count per min to microgram of protein for WI1 was about 2 times greater than WI2 
(Table 2). It is ideal to have roughly the same count per min to microgram of protein with 
in the sets. This variation was also seen with the cells that were not treated with insulin.  
Table 2. Results From Phase 1 of Glucose Uptake Assay  
 
The second phase of the experiment was attempted with four sets of cells (WOI, 
WOI/WC, WI, and WI/WC). It would be ideal to have at least duplicates of each set of 
cells, however, contamination occurred in eight out of the twelve plates. Another problem 
occurred when the colorimeter was giving sporadic absorbance readings and the amount 
Phase	1	Results
Sample Concentration(μg	of	protein/mL) μg	of	protein Counts	per	minute(cpm) cpm/μg	of	protein
WI1 79 2.4 4950 2100
WI2 130 4.0 4904 1300
WOI1 120 3.7 963 260
WOI2 110 3.3 1242 370
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of protein for each plate was unreliable. The scintillation data showed that cells that were 
treated with insulin had a greater count per minute than cells that were treated with both 
insulin and cytochalasin B (Table 3). However, cells without insulin had higher cpm than 
those with insulin. This could be attributed to differences in cell number, but we could 
not confirm this because of the problems with the absorbance measurements in the 
Bradford assay. 
Table 3. Results From Phase 2 of Glucose Uptake Assay 
 
 
  
Phase	2	Results
Sample cpm
WOI 23066
WOI/WC 17148
WI 18866
WI/WC 8505
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CHAPTER 5 
CONCLUSION / FUTURE WORK 
Hybrid inositiol glycans have been previously shown to elicit insulin mimetic effects. 
The goal of this study was to synthesize a library of novel HIGAs to explore the effects 
of the various non-carbohydrate moieties in hopes of increased potency of the insulin 
mimetic effects. Another goal of this study was to establish a glucose uptake assay that is 
capable of measuring the insulin-like effects of the HIGA. Unfortunately, a library of the 
desired HIGAs was not completed and a reliable glucose uptake assay was not 
established. A novel strategy was proposed to replace the 6’-thiol linkage with an amine 
linkage to avoid dimerization.  However, further steps were not attempted on the 6’-
amine linkage to determine whether this method is a more convenient way to form the 
glycosl donor. The furthest point in the synthetic scheme achieved was the formation of 
the 6’-phthalimide compound. 
Future work for this project would be to form the inositol acceptor starting from the 
conduritol and attempt the coupling of the glycosyl donor and inositol acceptor. Once that 
has been completed, reduction of phthalimide and linkage to a non-carbohydrate moiety 
can be carried out. It would be interesting to find optimal conditions for the global 
deprotection while also finding non-carbohydrate moieties that are able to sustain those 
conditions. After the successful synthesis of the HIGAs, it is important to establish a 
reproducible glucose uptake assay. The most important factor is to reduce contamination 
during cell culturing and to have a reliable colorimeter at hand.  
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CHAPTER 6  
EXPERIMENTAL 
6.1 General Methods 
All reagents and solvents were purchased from Sigma Aldrich or Fischer Scientific 
and were not further purified unless specified. All non-aqueous reactions were carried 
under argon or nitrogen atmosphere. Starting materials for the non-aqueous reactions 
were evaporated three times with toluene at 10-15 Torr and 45°C. Reactions were 
monitored by using thin layer chromatography on Baker glass backed silica plates 
(0.25mm) with a 254nm fluorescent indicator. Purification of the compounds was carried 
out via TLC with Baker glass backed silica plates (0.25mm) or flash chromatography 
with Baker silica gel (particle size 40-50 nm). 1H NMR data were obtained using 
Inova400 MHz spectrometer and samples were dissolved in CDCl3. Mass spectrometry 
data were obtained using electrospray ionization.  
6.2 Procedures 
2-azido-2-deoxy-1,3,4,6-tetra-O-acetyl -β-D-glucopyranoside (3) 
 
Triflic azide was prepared by dissolving sodium azide (10.857 g, 0.167 mol) in 200 
mL of dry acetonitrile at 0°C and was allowed to stir for 15 min. Through a dropping 
funnel, trifluoromethane sulfonic anhydride (23.4 ml, 0.139 mol) was added to the 
solution drop wise for 30 min. Once all the contents were added to the reaction flask, the 
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reaction was maintained at 0°C to yield a yellow solution. The diazotransfer was carried 
out by dissolving 1(24.99 g, 0.116 mol) in 120 mL of water. Cu(II)SO4 (0.2005 g, 0.125 
mmol) and triethylamine (32.4 mL, 0.236 mol) was added to the glucosamine solution 
and stirred at 0°C. Triflicazide was then added drop wise through a dropping funnel for 
10 min and the ice bath was removed. The reaction was allowed to run for 16 h before 
adding glycine (20.36 g, 0.271 mol) to quench the reaction and allowed to stir for another 
12 h. The reaction mixture was filtered and solvent was removed using rotary 
evaporation. The yellow crude was used for the next reaction without purification. The 
peractylation reaction was carried out by transferring 235 mL of dry pyridine into the 
reaction flask containing the diazo compound via cannula. Acetic anhydride was added 
through a dropping funnel over 45 min and the solution was allowed to stir at 0°C. Once 
all of the acetic anhydride was added, the reaction was allowed to stir for another 15 min 
and the ice bath was removed. The reaction went to completion after another 18 h of 
stirring at room temperature.  The reaction was worked up by initially washing the crude 
with NaHCO3. The solution was filtered and transferred to a separatory funnel to be 
extracted with dichloromethane (5 x 40 mL). The organic layer was collected and washed 
with 1 M HCl (2 x 500 mL) to remove residual pyridine. The organic solution was dried 
with MgSO4. Flash chromatography was carried with a 2.5% EtOAc : 97.5% (Rf=0.18) 
dichloromethane solvent system to yield 30.83 g (71% yield over two steps). 1H NMR δ 
2.02 (s, 3H, Ac), 2.07(s, 3H, Ac), 2.09 (s, 3H, Ac), 2.18 (s, 3H, Ac), 3.66 (m, 1H, H-6a), 
3.79 (dd, 1H, H-5), 4.07 (dd, 1H, H-6b), 4.29 (dd, 1H, H-2), 5.12-4.99 (m, 2H, H-3, H-4), 
5.54 (d,1H, H-1). 
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3,4,6-Tri-O-acetyl-2-Azido-2-deoxy-1-O-tert-buyldimethylsilyl-β-D-glucopyranoside 
(5) 
 
Compound 3 (4.33 g, 11.60 mmol) was dissolved in 43 mL of a dry THF/methanol 
solvent mixture (7:3) at 0°C. Gaseous anhydrous ammonia was then bubbled through for 
20 min. Shortly after, argon was bubble through to remove residual gaseous ammonia 
and the solvent was removed using rotary evaporation. The brown oil crude was used to 
carry out the silylation reaction without purification. The brown oil was evaporated 2x 
with toluene and dissolved in 22 mL of dry dichloromethane. Imidazole (1.44 g, 21.15 
mmol) was added followed by tert-butyldimethylsilyl chloride (1.90 g, 12.66 mmol) and 
the reaction was allowed to run for 2h to completion. The reaction was worked up by 
initially diluting the reaction with 10 mL of EtOAc.  Next, the mixture was washed with 
water and extracted with 1M HCl (3x 35 mL). Finally, the organic layer was washed one 
more time with water and dried with MgSO4. The solvent was removed using rotary 
evaporation and the compound was purified using flash chromatography with a 30% 
methanol: 70% dichloromethane solvent system (Rf=0.20) to yield 2.88 g of pure 
compound (55.7% yield). 1H NMR δ 0.15 (s, 6H, TBS), 0.95 (s, 9H, TBS) 2.00 (s, 3H, 
Ac), 2.08(s, 3H, Ac), 2.10 (s,3H,Ac), 3.40(m, 1H, H-6a), 3.64(dd, 1H, H-5), 4.09(dd, 1H, 
H-6b), 4.20(dd, 1H, H-2), 4.63(d, 2H, H-1) , 4.90( m, 1H, H-3,H-4)(Figure 5). 
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Figure 5. 1H NMR spectra of 3,4,6-Tri-O-acetyl-2-Azido-2-deoxy-1-O-tert-
buyldimethylsilyl-β-D-glucopyranoside. 
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2-Azido-2-deoxy-1-O-tert-butyldimethylsilyl-β-D-glucopyranoside (6) 
 
A 25% sodium methoxide solution was prepared by dissolving sodium metal (0.095 
g, 4.1 mmol) in 5 mL of dry methanol. In a separate flask, 5 (0.1035 g, 0.232 mmol) 
dissolved in 0.1 mL of dry methanol. 0.9 mL of the sodium methoxide solution was 
transferred into the reaction flask containing 5 and allowed to stir for 16 min. The 
reaction was worked up by adding DOWEX-50 acidic resin to the solution until the pH 
reached 4-6. The DOWEX resin was then filtered out and the solvent was removed by 
rotary evaporation to yield a yellow oil. The crude was subjected to flash chromatography 
with a 12% methanol: 88% dichloromethane solvent system (Rf = 0.23) to yield 65 mg of 
pure product (86% yield). 
2-Azido-2-deoxy-6-O-(4,4’-dimethoxytrityl)-1-O-tertbutyldimethylsilyl-β-D-
glucopyranoside 
 
 
 
Compound 6 (50.1 mg, 0.157 mmol) was dissolved in 1.1 mL of dry pyridine. 
DMTCl (66 mg, 0.195 mmol) was then added to the solution and allowed to stir for 6 h. 
An additional amount of DMTCl (66 mg, 0.195 mmol) was added and after 30 h. The 
reaction failed to go to completion and was stopped by adding 1 mL of ice-cold water. 
The solution was extracted with chloroform (5 x 1 mL) and the combined organic layers 
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were then washed with brine and evaporated by rotary evaporation. The contents were 
then triturated with heptane and the recovered crude was subjected to flash 
chromatography with a 30% EtOAc: 70% hexanes solvent system (Rf=0.25). 46.4 mg of 
pure product was recovered (44% yield).1H NMR δ 0.15 (s, 6H, TBS), 0.95 (s, 9H,TBS), 
2.6 (bs, 1H ), 2.65 (bs, 1H), 3.2-3.7 (m; 6H; H-2, H-3, H-4, H-5, H6a, H-6b), 3.8 (s, 3H, 
DMT), 4.55 (d, 1H, H-1), 6.7-7.5 (m, 13H, DMT).  
2-Azido-2-deoxy-4,6-O-benzylidene-1-O-tert-butyldimethylsilyl-β-D-
glucopyranoside (7) 
 
 
Compound 6 (753 mg, 2.36 mmol) was coevaporated with toluene and then dissolved 
in 16.8 mL of dry acetonitrile in the presence 4-Angstrom molecular sieves. In a separate 
flask, p-toulenesulfonic acid monohydrate (11 mg, 0.058 mmol) was evaporated 2x with 
toulene and dissolved in 5 mL of dry acetonitrile. 0.3 mL of the p-toulene sulfonic acid 
solution was transferred into the flask containing 6 and the reaction was allowed to stir 
for 36 h. The reaction was worked up by adding sodium carbonate (105 mg) to quench 
the reaction for 30 min. Sodium bicarbonate was filtered out and solvent was evaporated. 
The crude was purified using flash chromatography with a 0.1% triethylamine: 19.9% 
ethylacetate: 80% hexanes solvent system(Rf=0.20). 850 mg of pure product was 
recovered (88% yield). 1H NMR δ 0.17 (s, 3H, TBS), 0.18 (s, 3H, TBS), 0.96 (s, 9H, 
TBS), 2.90 (bs, 1H, OH), 3.22-3.82 (m; 5H; H-2, H-3, H-4, H-5, H-6), 4.29 (dd; 1H; H-
O
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6), 4.61 (d, 1H, H-1), 5.41 (s, 1H, acetal), 7.20-7.55 (m, 5H, Ph)(Figure 6).  
 
                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 1H NMR spectra of 2-Azido-2-deoxy-4,6-O-benzylidene-1-O-tert-
butyldimethylsilyl-β-D-glucopyranoside. 
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2-Azido-2-deoxy-4,6-O-benzylidene-3-O-p-methoxybenzyl-1-O-tert-
butyldimethylsilyl-β-D-glucopyranoside 
 
P-methoxybenzyltrichloroacetimidate was formed by dissolving 4-methoxybenzyl 
alcohol (1.500 g, 10.86 mmol) in 15 mL of dry dichloromethane. 1.5 mL of a 50% KOH 
solution was then added along with tetra-n-butyl ammonium hydrogen sulphate (15 mg, 
0.044 mmol) and stirred at -15 °C. After 5 min, trichloroacetonitrile was added (9 mL, 
0.090 mol) and the reaction was allowed to stir for another 30 min at -15 °C. After 30 
min, the dried ice bath was removed and the reaction was allowed to run for 24 h. The 
solution was extracted with dichloromethane (5 x 10 mL) and the combined organic layer 
was dried over MgSO4. MgSO4 was filtered off and the resulting solution was passed 
through a thin silica pad and washed with 20 mL of dichloromethane. In a separate flask 
containing 7 (315 mg, 0.77 mmol), p-methoxybenzyltrichloroacetimidate (1.5 mL, 7.22 
mmol) was added in the presence of 4-Angstrom molecular sieves. The contents were 
then dissolved in 4.7 mL of dry dichloromethane and BF3 etherate was added at 0°C. The 
ice bath was then immediately removed. After 18 h, additional amounts of p-
methoxybenzyltrichloroacetimidate (1.5 mL, 7.22 mmol) was added but the reaction still 
failed to go to completion. After 36 h, the reaction was stopped by adding 3 mL of 
triethylamine. The solvent was then evaporated using rotary evaporation to yield a yellow 
oil. The crude was purified using flash chromatography with a 0.1% triethylamine: 6.9% 
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EtOAc : 93% hexanes solvent system (Rf = 0.18) to yield 94 mg of pure product (23% 
yield).1H NMR δ 0.12 (s, 3H, TBS), 0.13 (s, 3H, TBS), 0.91 (s, 9H, TBS), 3.29-3.42 (m; 
2H; H-5, H-6a), 3.49 (t, 1H, H-4), 3.68 (t, 1H, H-2), 3.76 (t, 1H, H-3), 3.80 (s, 3H, PMB), 
4.26 (dd; 1H; J=4.99,10.5Hz, H-6b), 4.57 (d, 1H, J=7.59Hz, H-1), 4.78 (d, 1H, PMB), 
4.88 (d, 1H, J=11.39Hz, PMB), 5.51 (s, 1H, acetal), 6.8-7.5 (m, 10H, Ph/PMB).  
2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-1-O-tert-butyldimethylsilyl-β-D-
glucopyranoside (8). 
 
 
Compound 7 (474 mg, 1.16 mmol) was evaporated 2x with toluene and dissolved in 
23 mL of dry THF.  At 0°C, NaH (278.9 mg, 11.62 mmol) was added and the ice bath 
was then immediately removed. After the reaction was allowed to reach room 
temperature, BnBr (350 µL, 2.95 mmol) was added at 0°C. Once BnBr was added, the ice 
bath was once again removed allowing the reaction to reach room temperature and TBAI 
(16.7 mg, .045 mmol) was subsequently added. The reaction was allowed to run for 5.5 h 
to completion and the reaction was stopped by adding 25 mL of ice cold water at 0°C. 
The solution was extracted with EtOAc (5 x 25mL) and the combined organic layers 
were dried using MgSO4. MgSO4 solvent was removed using rotary evaporation to yield 
a yellow/white heterogeneous solid. Dry packing method was necessary when loading the 
compound into the column for flash chromatography. A 4% EtOAc: 96% hexanes solvent 
system was used to recover 500 mg of pure compound (86.3% yield). 1H NMR 0.15 (s, 
3H, TBS), 0.16 (s, 3H, TBS), 0.91 (s, 9H, TBS), 3.3-3.41 (m; 2H; H-5, H-6a), 3.50 (t, 
O
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1H, H-4), 3.69 (t, 1H, H-2), 3.78 (t, 1H, H-3), 4.28 (dd; 1H; H-6b), 4.57 (d, 1H, H-1), 
4.78 (d, 1H, Bn), 4.84 (d, 1H, J=11.4Hz, Bn), 5.55 (s, 1H, Acetal), 7.2-7.5 (m, 10H, 
Bn/Ph).  
2-Azido-3,4-di-O-benzyl-2-deoxy-1-O-tert-butyldimethylsilyl-β-D-glucopyranoside 
(9). 
 
Compound 8 (134 mg, 0.269 mmol) was evaporated 2x with toluene. BH3NH3 was 
added to reaction flask and dissolved in 2.8 mL of dry dichloromethane. BF3etherate was 
then added in a dropwise fashion and the reaction was allowed to run for 15 min. After 
the reaction reached completion, 4 mL of EtOAc was added to dilute the reaction and the 
solution was then washed with NaHCO3 (3 x 5 mL). The organic layers were combined 
and then extracted with NaCl (2 x 5mL) and dried with MgSO4. Flash chromatography 
was used to purify the crude (yellow oil) with a 4% EtOAc:  96% hexanes solvent system 
(Rf=0.10) to recover 0.103 mg of pure product (77% yield). 1H NMR 0.155 (s, 3H, TBS), 
0.163 (s, 3H, TBS), 0.94 (s, 9H, TBS), 3.2-3.9 (m; 6H; H-2, H-3, H-4, H-5, H6a, H-6b), 
4.54 (d, 1H, H-1), 4.63 (d, 1H, Bn), 4.95 (d, 1H, Bn), 4.84 (d, 1H, Bn), 4.89 (d, 1H, 
J=7.8Hz, Bn), 7.20- 7.45 (m, 10H, Bn). 
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2-Azido-2-deoxy-3,4-di-O-benzyl-6-tosyl-6-deoxy-1-O-tert-butyldimethylsilyl-β-D-
glucopyranoside (10). 
 
Compound 9 (25.8 mg, 0.052 mmol) was evaporated 2x with toluene and dissolved in 
1.2 mL of dry pyridine. P-toulenesulfonyl chloride (0.128 g, 0.671 mmol) was added 
at0°C and the ice bath was removed immediately after. The reaction was allowed to run 
for 21 h to completion and was quenched with 2 mL of ice cold water at 0°C. The 
solution was then extracted with chloroform (5 x 4 mL) and the combined organic layers 
were dried with MgSO4. The solvent was evaporated using rotary evaporation and the 
yellow oil crude was purified using preparatory thin layer chromatography with a 3% 
EtOAc: 97% hexanes solvent system (R = 0.23). The purification yielded 22 mg of a 
yellow oil (65% yield).1H NMR δ 0.095 (s, 3H,TBS), 0.114 (s, 3H, TBS), 0.903 (s, 9H, 
TBS), 2.43 (s, 3H, Ts), 3.2- 3.5 (m; 4H; H-2, H-3, H-4, H-5), 4.06 (dd, 1H, H-6a), 4.16 
(dd, 1H, H-6b), 4.45 (d, H-1), 4.50 (d, 1H, Bn), 4.75 (d, 1H, J=10.8Hz, Bn), 4.80 (d, 1H, 
Bn), 4.90 (d, 1H, Bn), 7.1-7.4 (m, 14H, Bn).  
2-Azido-2-deoxy-3,4-di-O-benzyl-6-thiobenzyl-6-deoxy-1-O-tert-butyldimethylsilyl-
β-D-glucopyranoside (10). 
 
 
66 µL of BnSH (0.556 mmol) was dissolved in 0.450ml of dry THF and at 0°C. 1.03 mL 
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of n-butyllithium in hexanes (0.556 mmol) was added to prepare the BnSLi solution. The 
ice bath was removed after the addition of n-butyllithium and the reaction was stirred at 
room temperature for 90 min. Separately, compound 10 (36.3 mg, 0.0556 mmol) was 
evaporated 2x with toluene and at 0°C, all of the BnSLi solution was added to the 
reaction flask. After 5 min, the ice bath was removed and allowed to react for 46 h at 
room temperature. The reaction flask was cooled to 0°C and 1 mL of ice cold water was 
added to quench the reaction. The mixture was then extracted with chloroform (3 x 1 mL) 
and the combined organic layer was dried with MgSO4. The mixture was concentrated in 
vacuo to yield a yellow oil. The oil was purified using preparatory thin layer 
chromatography using 80% hexanes: 10% ethyl acetate solvent system leading to the 
recovery of 15 mg (45% yield) of pure compound. 1H NMR δ 0.21 (s, 6H, TBS), 0.95 (s, 
9H, TBS), 2.53 (dd; 1H; H-6a), 2.79 (dd; 1H; H-6b), 3.3-3.5 (m; 4H; H-2, H-3, H-4, H- 
5), 3.71 (d, 1H, SBn) 3.77 (d, 1H, J=13.4Hz, SBn), 4.49 (d, 1H, H-1), 4.52 (d, 1H, Bn), 
4.76 (d, 1H, Bn), 4.82 (d, 1H, Bn), 4.84 (d, 1H, Bn), 7.1-7.4 (m, 15H, Bn).  
2-Azido-2-deoxy-3,4-di-O-benzyl-6-phthalimide-6-deoxy-1-O-tert-
butyldimethylsilyl-β-D-glucopyranoside. 
 
Compound 10 (12.8 mg, 0.020 mmol) was evaporated 3x with toluene and dissolved 
in 110 µL of hexamethylphosphoramide. Potassium phthalimide (8.89 mg, 0.048 mmol) 
was added to the reaction flask and allowed to react at 65°C for 3 h. Once the reaction 
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was complete, the mixture was cooled using ice bath and quenched with 3 mL of 
dichloromethane. The mixture was then washed with saturated NaSO4 (1 x 3 mL) and the 
resulting organic layer was washed with water (5x 3mL). The combined organic layers 
were washed once again with saturated NaSO4 (1x 3mL) and dried with NaSO4. After 
concentration in vacuo, a yellow crude oil was obtained. The crude oil was purified using 
preparatory thin layer chromatography with a 80% hexanes: 20% ethylacetate solvent 
system (Rf = 0.18) to yield 5.6mg(46%) of pure compound. 1H NMR δ 0.21 (s, 6H, 
TBS), 0.95 (s, 9H, TBS), 3.2-3.3 (dd; 1H; H-6a), 3.31-3.42 (dd; 1H; H-6b), 3.3-3.5 (m; 
4H; H-2, H-3, H-4, H- 5), 4.39 (d, 1H, H-1), 4.65 (d, 1H, Bn), 4.76 (d, 1H, Bn), 4.82 (d, 
1H, Bn), 4.92 (d, 1H, Bn), 7.1-7.2 (m, 10H, Bn) 7.6-7.8(dd, 4H, phthalimide). 
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Figure 7. 1H NMR spectra of 2-Azido-2-deoxy-3,4-di-O-benzyl-6-phthalimide-6-deoxy-
1-O-tert-butyldimethylsilyl-β-D-glucopyranoside. 
	 59 
 
 
Figure 8. Mass spectra of 2-Azido-2-deoxy-3,4-di-O-benzyl-6-phthalimide-6-deoxy-1-O-
tert-butyldimethylsilyl-β-D-glucopyranoside. 
	 60 
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